China Supply Reliable Manufacturers 99% CAS 910463-68-2 Semaglutide Peptides

Sales manager:Grace
whatsapp：+8693143642
Email:emma@lianyi-tech.cn

  Semaglutide is the latest GLP-1 receptor agonist and was approved by the FDA at the end of 2017 for once-weekly use in the treatment of type 2 diabetes. The peptide is chemically similar to liraglutide, with the inclusion of two structural modifications (Lau, Bloch, et al., 2015). The first is the replacement of Gly with the non-proteinogenic amino acid 2-aminoisobutyric acid (Aib) at position 2. The second is the attachment of octadecanoic diacid to the side chain of Lys-26 through a short polyethylene glycol (PEG) spacer and a γ-glutamic acid linker. The amino acid substitution renders the peptide more resistant to DPP-4 compared to liraglutide, and the presence of the 18-carbon fatty acid moiety results in a high binding affinity for serum albumin, which translates to a half-life of approximately 7 days in humans.  It is used to treat type 2 diabetes and manage chronic weight. The drug functions similar to human glucagon-like peptide-1 (GLP-1) by increasing secretion, which leads to improved sugar metabolism. 

   Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.

The storage conditions of Semaglutide are:
Before first use, store in the refrigerator at a temperature of 2°C-8°C, dry, protected from light, and sealed.
Do not freeze and do not use after freezing.
Keep out of reach of children.
In actual operation, the storage conditions recommended by the product instructions or doctors should be followed.